We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Symproic

News List

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic firstwordpharma
April 11, 2019
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical ……
Shionogi Regains Full Rights to Symproic (naldemedine) in the US firstwordpharma
July 10, 2018
OSAKA, Japan & FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") has announced that effective immediately
Fifty-Two Week Safety Study on Symproic® (naldemedine) for Opioid-induced Constipation (OIC) in Adul biospace
March 07, 2018
Shionogi, Inc and Purdue Pharma, L.P. today announced the publication of a study known as COMPOSE-3.